CeriBell, Inc. (NASDAQ:CBLL) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• CeriBell, Inc. (NASDAQ:CBLL) has received an average recommendation of "Moderate Buy" from nine brokerages, with one analyst issuing a sell rating and eight issuing buy ratings.
• CEO Xingjuan Chao sold 25,000 shares of the company at an average price of $17.70, reducing their ownership by 3.12%.
• The company reported a loss of $0.38 EPS for the last quarter, slightly outperforming analysts' expectations of a loss of $0.40.

Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $32.1429.

CBLL has been the topic of several research analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of CeriBell in a research note on Saturday, September 27th. BTIG Research initiated coverage on CeriBell in a research note on Tuesday, June 24th. They set a "buy" rating and a $30.00 price objective on the stock.

Insider Transactions at CeriBell

In related news, CEO Xingjuan Chao sold 25,000 shares of the firm's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the transaction, the chief executive officer directly owned 776,022 shares in the company, valued at $13,735,589.40. This trade represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Deutsche Bank AG grew its holdings in CeriBell by 0.4% during the first quarter. Deutsche Bank AG now owns 231,629 shares of the company's stock worth $4,450,000 after acquiring an additional 842 shares during the period. Ameritas Investment Partners Inc. boosted its stake in CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock valued at $48,000 after buying an additional 1,256 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in CeriBell by 0.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 416,908 shares of the company's stock worth $8,009,000 after purchasing an additional 1,547 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after purchasing an additional 1,801 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in CeriBell in the first quarter valued at about $36,000.

CeriBell Stock Up 7.0%

NASDAQ:CBLL traded up $0.83 during trading hours on Friday, hitting $12.64. The stock had a trading volume of 539,085 shares, compared to its average volume of 252,049. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The business has a 50 day simple moving average of $12.30 and a two-hundred day simple moving average of $15.52. The company has a market cap of $463.38 million and a PE ratio of -4.23.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $21.20 million during the quarter, compared to analysts' expectations of $20.52 million. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%. CeriBell has set its FY 2025 guidance at EPS. Analysts predict that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.